BioSpace News Archive

TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11th through Wednesday, September 13th starting at 7:00 a.m. ET.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces the U.S. Food and Drug Administration has granted Orphan Drug Designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia.

Valneva SE announced that Health Canada has completed screening validation of the Company’s regulatory application for marketing approval of its single-shot chikungunya vaccine candidate VLA1553 in persons aged 18 years and above, and has determined that the New Drug Submission application is sufficiently complete to permit a substantive review.

Orexo AB, announces that the United States Patent and Trademark Office has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors.

Clene Inc. through its wholly owned subsidiary Clene Nanomedicine Inc., announced the 24-month long-term data cut from the Phase 2 RESCUE-ALS ongoing open-label extension as of July 2023, which showed a significant median survival benefit of 19.3 months using the rank-preserving structural failure time model and a significant 52% decreased risk of ALS clinical worsening events with CNM-Au8® treatment.

Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate ESSOR, an adaptive Phase 2/3 randomized placebo-controlled trial testing its oral drug candidate LAU-7b as a potential treatment for Long COVID.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced that Chairman and CEO Brent Saunders is scheduled to participate at the 2023 Wells Fargo Healthcare Conference in Boston on Sept. 6, 2023, at 10:15 a.m. ET.

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced preliminary financial results for the fourth quarter of fiscal 2023, which ended June 30, 2023.

Reneo Pharmaceuticals, Inc. announced that the company’s management team will participate at the upcoming healthcare investor conferences.